Orum Therapeutics Inc. (Ticker: 475830 KS) is a South Korean biotechnology company that develops novel therapeutics, focusing on ADC (Antibody-Drug Conjugate) and TPD (Targeted Protein Degradation) technologies. The lead product candidate, ORM-6151 was licensed to Bristol-Myers Squibb in 2023. In July 2024, Orum Therapeutics entered into a technology transfer agreement with Vertex Pharmaceuticals, potentially worth up to $310 million per target for up to three targets.

Orum Therapeutics Inc. is expected to start trading on the KOSDAQ on February 14, 2025. The firm is selling 2.5 million shares, all primary, at a finalized price of KRW 20,000, which was below the initially proposed range of KRW 24,000-30,000. The expected Market Capitalization at offer is KRW 418.58 billion (USD $288.28 million). The total offer size is KRW 50 billion (USD $34.44 million), reduced from an initial filing amount of KRW 75 billion. The offering is managed by Korea Investment & Securities Co.